Screener
ClearPoint Neuro CLPT Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by ClearPoint Neuro in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: ClearPoint Neuro’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221890
| Line item | March 31, 2026 / (Unaudited) | December 31, 2025 |
|---|---|---|
| Accrued compensation | 2,977 | 4,360 |
| Other accrued liabilities | 2,125 | 2,786 |
| Operating lease liabilities, current portion | 234 | 694 |
| Contract liabilities, current portion | 1,814 | 1,669 |
| Total current liabilities | 9,480 | 10,765 |
| Operating lease liabilities, net of current portion | 13,710 | 8,461 |
| Contract liabilities, net of current portion | 608 | 581 |
| Long-term notes payable, net | 49,644 | 49,077 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is ClearPoint Neuro's deferred revenue?
- ClearPoint Neuro (CLPT) reported deferred revenue of $1.81M in Q1 2026.
- How has ClearPoint Neuro's deferred revenue changed year-over-year?
- ClearPoint Neuro's deferred revenue increased by 12.1% year-over-year, from $1.62M to $1.81M.
- What is the long-term trend for ClearPoint Neuro's deferred revenue?
- Over 5 years (2020 to 2025), ClearPoint Neuro's deferred revenue has grown at a 50.7% compound annual growth rate (CAGR), from $215K to $1.67M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about ClearPoint Neuro's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude